金迪克(688670.SH)：预计2025年度同比增亏71.12%到92.51%

Group 1 - The company expects a net loss attributable to shareholders of the parent company for 2025 to be between -180 million to -160 million yuan, representing an increase in loss of 66.49 million to 86.49 million yuan compared to the previous year, which is a year-on-year increase in loss of 71.12% to 92.51% [1] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -185 million to -165 million yuan, with an increase in loss of 58.78 million to 78.78 million yuan compared to the previous year, reflecting a year-on-year increase in loss of 55.33% to 74.16% [1] - The company has completed the enrollment of subjects for the Phase III clinical trial of the quadrivalent influenza virus split vaccine (for children) and has finished the vaccination process, with serum currently undergoing inspection at the National Medical Products Administration [1] Group 2 - Due to equipment failures and differences in consumable batches, the company has decided not to sell certain in-process and finished products, adhering to a cautious principle [2] - The quadrivalent influenza virus split vaccine has a shelf life of 12 months from the date of production, and any unadministered vaccines at the end of each flu season must be disposed of according to relevant laws and regulations [2] - The company has made provisions for asset impairment and inventory write-offs totaling approximately 41.99 million yuan, based on market research and historical return rates [2]